• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Ault Global Holdings Reports Second Quarter 2021 Results

    8/16/21 6:30:00 AM ET
    $ALZN
    $DPW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Machinery/Components
    Capital Goods
    Get the next $ALZN alert in real time by email

    Q2 2021 Revenue of $62.1 Million, up 1050% From the Prior Year's Quarter

    Q2 2021 Net Income of $42.2 Million Compared to a $1.4 Million Loss in the Prior Year's Quarter

    Total Assets of More Than a Quarter of a Billion Dollars ($259.1 Million)

    Ault Global Holdings, Inc. (NYSE:DPW) a diversified holding company (the "Company"), today announced its financial results for the second quarter ended June 30, 2021.

    Q2-2021 highlights

    • Revenue of $62.1 million, an increase of 1050% from $5.4 million in the prior second fiscal quarter;
    • Revenue from lending and trading activities of $53.3 million due to the allocation of capital to the Company's wholly owned subsidiary, Digital Power Lending, LLC ("DP Lending");
    • Revenue from lending and trading activities includes an approximate $40 million unrealized gain from the Company's investment in Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders;
    • Revenue from cryptocurrency mining of $291,000 as the Company resumed cryptocurrency mining operations with approximately 1,000 miners during March 2021;
    • Net income of $42.2 million for the quarter, which represents the largest quarterly profit in Company history;
    • Positive working capital of $127.9 million;
    • Total assets of more than a quarter-of-a-billion dollars ($259.1 million); and
    • Cash of $105.4 million, marketable securities of $30.2 million and other investments of $81.5 million as of June 30, 2021.

    Six months ended June 30, 2021 highlights

    • Revenue of $75.4 million, an increase of 585% from $11.0 million in the prior six-month period;
    • Revenue from lending and trading activities of $58.5 million due to the allocation of capital to DP Lending;
    • Revenue from cryptocurrency mining of $421,000 as the Company resumed cryptocurrency mining operations with approximately 1,000 miners during March 2021; and
    • Net income of $44.2 million compared to a net loss of $7.9 million in the prior six-month period.

    Revenues

    Revenues by segment for the three months ended June 30, 2021 and 2020 were as follows:

    For the Three Months Ended June 30,

    2021

    2020

    Increase

    %

     

    Gresham Worldwide ("GWW")

    $

    6,475,000

     

    $

    4,189,000

     

    $

    2,286,000

     

    55%

    Coolisys Technologies Corp. ("Coolisys")

     

    1,831,000

     

    1,246,000

     

    585,000

    47%

    Ault Alliance:

     

     

     

     

     

     

     

    Revenue, cryptocurrency mining

     

    291,000

     

    —

     

    291,000

    —

    Revenue, lending and trading activities

     

    53,274,000

     

     

    (34,000)

     

     

    53,308,000

     

    156788%

    Other

    $

    258,000

     

    —

     

    258,000

    —

    Total revenue

    $

    62,129,000

     

    $

    5,401,000

     

    $

    56,728,000

     

    1050%

    GWW

    GWW's revenues increased by $2.3 million, or 55%, to $6.5 million for the three months ended June 30, 2021, from $4.2 million for the three months ended June 30, 2020. GWW revenue in 2021 includes $1.7 million from Relec, which was acquired on November 30, 2020. In addition, the increase in revenue from our GWW segment for customized solutions for the military markets reflected the benefit of capital that was allocated to our defense business based on the overall improved capital structure of the Company.

    Coolisys

    Coolisys' revenues increased by $586,000 or 47%, to $1.8 million for the three months ended June 30, 2021, from $1.2 million for three months ended June 30, 2020. The increase is due, in part, to the lack of disruptions to Coolisys' business operations, which Coolisys experienced in the prior year period related to the temporary suspension of operations related to the outbreak of COVID-19.

    Ault Alliance

    Revenues from our cryptocurrency mining operations were $291,000 for the three months ended June 30, 2021, compared to nil for the three months ended June 30, 2020, as we resumed our cryptocurrency mining operations during the first quarter of 2021. Our decision to resume cryptocurrency mining operations in 2021 was based on several factors, including the market prices of digital currencies, and favorable power costs available at our Michigan Data Center, operated by our majority owned subsidiary Alliance Cloud Services, LLC ("Alliance").

    Revenues from our lending and trading activities increased to $53.3 million for the three months ended June 30, 2021, from negative revenues of $34,000 for the three months ended June 30, 2020, which is attributable to a significant allocation of capital from our recent equity financing transactions to our loan and investment portfolio. During the three months ended June 30, 2021, DP Lending generated significant income from appreciation of investments in marketable securities as well as shares of common stock underlying convertible notes and warrants issued to DP Lending in certain financing transactions. Under its business model, DP Lending also generates revenue through origination fees charged to borrowers and interest generated from each loan.

    Revenues from our trading activities in 2021 included significant net gains on equity securities, including unrealized gains and losses from market price changes. These gains and losses have caused, and will continue to cause, significant volatility in our periodic earnings.

    Gross margins

    Gross margins increased to 89.9% for the three months ended June 30, 2021 compared to 37.1% for the three months ended June 30, 2020. Our gross margins have typically ranged between 33% and 37%, with slight variations depending on the overall composition of our revenue.

    Our gross margins of 89.9% recognized during the three months ended June 30, 2021 resulted from the favorable margins from our lending and trading activities. Excluding the effects of margin from our lending and trading activities, our adjusted gross margins for the three months ended June 30, 2021, would have been 29%, slightly lower than our historical range.

    Operating expenses

    Operating expenses increased to $10.0 million for the three months ended June 30, 2021, representing an increase of $7.3 million compared to $2.7 million for the three months ended June 30, 2020.

    The increase in operating expenses from the three months ended June 30, 2020 was due to the following:

    • Research and development expenses increased by $69,000 to $531,000 for the three months ended June 30, 2021, from $462,000 for the three months ended June 30, 2020. The increase in research and development expenses is due to costs incurred by Coolisys related to the development of our electric vehicle charger products;
    • Selling and marketing expenses were $1.5 million for the three months ended June 30, 2021, compared to $295,000 for the three months ended June 30, 2020, an increase of $1.2 million, or 410%. The increase was in part the result of increases in personnel costs directly attributable to the increase in sales and marketing personnel and consultants, primarily at Ault Alliance related to digital marketing and digital learning. The increase is also attributable to costs incurred at Coolisys to grow our selling and marketing infrastructure related to our electric vehicle charger products;
    • General and administrative expenses were $8.0 million for the three months ended June 30, 2021, compared to $2.9 million for the three months ended June 30, 2020, an increase of $5.1 million. General and administrative expenses increased from the comparative prior period due mainly to:
      • the accrual of a $2.9 million performance bonus related to trading activities during the period;
      • non-cash stock compensation costs of $545,000 related to GWW options and shares issued to GWW's Chief Executive Officer and Chief Operating Officer;
      • general and administrative costs of $363,000 related to Relec, which was acquired on November 30, 2020;
      • increased costs related to our Michigan Data Center; and
      • higher consulting, audit, legal and insurance costs; and
    • The three months ended June 30, 2020 included a $1.0 million reversal of a provision for credit losses.

    The Company's Chief Financial Officer, Kenneth S. Cragun, said, "The financial results for the second quarter of 2021 demonstrate that we are continuing to achieve our objectives to grow revenue and improve operating results, with revenue growth of 1050% over the prior second fiscal quarter and net income of $42.2 million. We saw tremendous growth from our lending and trading activities with the infusion of capital and growth in all of our business segments. Our balance sheet remains strong, ending the second quarter of 2021 with positive working capital of $127.9 million."

    The Company's Founder and Executive Chairman, Milton "Todd" Ault, III said, "Our results for the second quarter of 2021 reflect the strength of our lending and trading activities at DP Lending, our financial services subsidiary. We believe our current lending and investing pipeline is strong and if the market conditions for investing in small cap stocks remains strong, the future prospects for the Company are extremely promising. Quite simply, we are in the strongest position of our Company's 52-year history. We have grown assets to more than a quarter of a billion and are announcing a goal to grow assets to more than one billion dollars. Over the longer term, we envision allocating $250 million to DP Lending, $250 million to real estate investments, and $500 million to completing acquisitions of profitable companies, or distressed companies that we believe we can make profitable. As discussed in the previous quarter, our near-term key initiatives include:

    • Exploring a potential IPO or other transaction to access capital markets for our GWW defense business;
    • Exploring a potential IPO for our power electronics and electric vehicle charger business;
    • Completing the initial 30,000 square foot buildout of our Michigan Data Center;
    • Ramping up cryptocurrency mining operations at our Michigan Data Center;
    • Ramping up fulfillment of the $50 million MTIX purchase order for MLSE plasma-laser systems;
    • Expanding our loan and investment portfolio at DP Lending; and
    • Considering further acquisitions.

    Considering our subsidiaries operating in the sectors of defense, electric vehicle chargers, power electronic businesses, data center, crypto mining, lending and investment platform, the road ahead is bright."

    For more information on Ault Global Holdings and its subsidiaries, the Company recommends that stockholders, investors and any other interested parties read the Company's public filings and press releases available under the Investor Relations section at www.AultGlobal.com or available at www.sec.gov.

    About Ault Global Holdings, Inc.

    Ault Global Holdings, Inc. is a diversified holding company pursuing growth by acquiring undervalued businesses and disruptive technologies with a global impact. Through its wholly and majority-owned subsidiaries and strategic investments, the Company provides mission-critical products that support a diverse range of industries, including defense/aerospace, industrial, automotive, telecommunications, medical/biopharma, and textiles. In addition, the Company extends credit to select entrepreneurial businesses through a licensed lending subsidiary. Ault Global Holding's headquarters are located at 11411 Southern Highlands Parkway, Suite 240, Las Vegas, NV 89141; www.AultGlobal.com.

    Forward-Looking Statements

    This press release contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "believes," "plans," "anticipates," "projects," "estimates," "expects," "intends," "strategy," "future," "opportunity," "may," "will," "should," "could," "potential," or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect the Company's business and financial results are included in the Company's filings with the U.S. Securities and Exchange Commission, including, but not limited to, the Company's Forms 10-K, 10-Q and 8-K. All filings are available at www.sec.gov and on the Company's website at www.AultGlobal.com.

    AULT GLOBAL HOLDINGS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Unaudited)

     

    June 30,

    December 31,

    2021

    2020

    ASSETS

     

    CURRENT ASSETS

     

     

     

    Cash and cash equivalents

    $

    105,391,000

    $

    18,680,000

    Marketable equity securities

     

    30,172,000

     

     

    2,563,000

    Accounts receivable

     

    4,730,000

     

    3,852,000

    Accounts and other receivable, related party

     

    1,196,000

     

     

    1,196,000

    Accrued revenue

     

    1,594,000

     

    1,696,000

    Inventories

     

    2,900,000

     

     

    3,374,000

    Prepaid expenses and other current assets

     

    5,373,000

     

    2,988,000

    TOTAL CURRENT ASSETS

     

    151,356,000

     

     

    34,349,000

     

    Intangible assets, net

     

    4,175,000

     

     

    4,390,000

    Goodwill

     

    9,589,000

     

    9,646,000

    Property and equipment, net

     

    7,262,000

     

     

    2,123,000

    Right-of-use assets

     

    4,605,000

     

    4,318,000

    Investment in promissory notes, related parties

     

    13,913,000

     

     

    10,668,000

    Investments in common stock and warrants, related parties

     

    60,355,000

     

    6,139,000

    Investments in debt and equity securities

     

    4,013,000

     

     

    262,000

    Investment in limited partnership

     

    1,869,000

     

    1,869,000

    Loans receivable

     

    572,000

     

     

    750,000

    Other investments, related parties

     

    788,000

     

    803,000

    Other assets

     

    604,000

     

     

    326,000

    TOTAL ASSETS

    $

    259,101,000

    $

    75,643,000

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

     

    CURRENT LIABILITIES

    Accounts payable and accrued expenses

    $

    7,784,000

     

    $

    10,579,000

    Accounts payable and accrued expenses, related party

     

    —

     

    36,000

    Operating lease liability, current

     

    876,000

     

     

    524,000

    Revolving credit facility

     

    103,000

     

    125,000

    Notes payable, net

     

    1,808,000

     

     

    4,048,000

    Notes payable, related parties

     

    —

     

    188,000

    Convertible notes payable, related party

     

    —

     

     

    400,000

    Warrant liability

     

    4,580,000

     

    4,192,000

    Income taxes payable

     

    2,770,000

     

     

    —

    Other current liabilities

     

    5,572,000

     

     

    1,790,000

    TOTAL CURRENT LIABILITIES

    $

    23,493,000

    $

    21,882,000

    AULT GLOBAL HOLDINGS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS (continued)

    (Unaudited)

     

    June 30,

    December 31,

    2021

    2020

    LONG TERM LIABILITIES

    Operating lease liability, non-current

     

    3,792,000

     

     

    3,855,000

    Notes payable

     

    —

     

    336,000

    Notes payable, related parties

     

    —

     

     

    52,000

    Convertible notes payable

     

    427,000

     

    386,000

     

    TOTAL LIABILITIES

     

    27,712,000

     

    26,511,000

     

    COMMITMENTS AND CONTINGENCIES

     

     

     

     

    STOCKHOLDERS' EQUITY

     

     

     

    Series A Convertible Preferred Stock, $25.00 stated value per share,

     

    —

     

    —

    $0.001 par value – 1,000,000 shares authorized; 7,040 shares

    issued and outstanding at June 30, 2021 and December 31, 2020

    (redemption amount and liquidation preference of $176,000

    as of June 30, 2021 and December 31, 2020)

    Series B Convertible Preferred Stock, $10 stated value per share,

     

    —

     

     

    —

    $0.001 par value – 500,000 shares authorized; 125,000 shares issued

     

     

     

    and outstanding at June 30, 2021 and December 31, 2020 (liquidation

     

     

     

    preference of $1,250,000 at June 30, 2021 and December 31, 2020)

     

     

     

    Class A Common Stock, $0.001 par value – 500,000,000 shares authorized;

     

    56,000

     

    28,000

    56,159,963 and 27,753,562 shares issued and outstanding at June 30,

    2021 and December 31, 2020, respectively

    Class B Common Stock, $0.001 par value – 25,000,000 shares authorized;

     

    —

     

     

    —

    nil shares issued and outstanding at June 30, 2021 and December 31,

    2020

     

     

     

    Additional paid-in capital

     

    311,760,000

     

    171,397,000

    Accumulated deficit

     

    (77,190,000)

     

     

    (121,397,000)

    Accumulated other comprehensive gain (loss)

     

    (4,601,000)

     

    (1,718,000)

    TOTAL AULT GLOBAL HOLDINGS STOCKHOLDERS' EQUITY

     

    230,025,000

     

     

    48,310,000

     

    Non-controlling interest

     

    1,364,000

     

     

    822,000

     

    TOTAL STOCKHOLDERS' EQUITY

     

    231,389,000

     

     

    49,132,000

     

    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

    $

    259,101,000

     

    $ 

    75,643,000 

    AULT GLOBAL HOLDINGS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS) (Unaudited)

     

    For the Three Months Ended

    For the Six Months Ended

    June 30,

    June 30,

    2021

    2020

    2021

    2020

    Revenue

    $

    8,564,000

     

    $

    5,435,000

     

    $

    16,469,000

     

    $

    11,004,000

    Revenue, cryptocurrency mining

     

    291,000

     

    —

     

    421,000

     

    —

    Revenue, lending and trading activities

     

    53,274,000

     

     

    (34,000)

     

     

    58,485,000

     

     

    2,000

    Total revenue

     

    62,129,000

     

    5,401,000

     

    75,375,000

     

    11,006,000

    Cost of revenue

     

    6,278,000

     

     

    3,496,000

     

     

    11,386,000

     

     

    7,349,000

    Gross profit

     

    55,851,000

     

    1,905,000

     

    63,989,000

     

    3,657,000

     

    Operating expenses

     

     

     

     

     

     

     

    Research and development

     

    531,000

     

    462,000

     

    1,133,000

     

    903,000

    Selling and marketing

     

    1,505,000

     

     

    295,000

     

     

    2,747,000

     

     

    633,000

    General and administrative

     

    7,992,000

     

    2,918,000

     

    13,084,000

     

    5,821,000

    Provision for credit losses

     

    —

     

     

    (1,000,000)

     

     

    —

     

     

    —

    Total operating expenses

     

    10,028,000

     

    2,675,000

     

    16,964,000

     

    7,357,000

    Income (loss) from continuing operations

     

    45,823,000

     

     

    (770,000)

     

     

    47,025,000

     

     

    (3,700,000)

    Other income (expenses)

    Interest income

     

    14,000

     

     

    36,000

     

     

    51,000

     

     

    36,000

    Interest expense

     

    (22,000)

     

    (963,000)

     

    (337,000)

     

    (2,049,000)

    Change in fair value of marketable equity securities

     

    (1,915,000)

     

     

    337,000

     

     

    45,000

     

     

    (29,000)

    Realized gain on marketable securities

     

    —

     

    —

     

    397,000

     

    —

    Gain (loss) on extinguishment of debt

     

    447,000

     

     

    (12,000)

     

     

    929,000

     

     

    (475,000)

    Change in fair value of warrant liability

     

    290,000

     

    (10,000)

     

    (388,000)

     

    (6,000)

    Total other income (expenses), net

     

    (1,186,000)

     

     

    (612,000)

     

     

    697,000

     

     

    (2,523,000)

    Income (loss) from continuing operations before income taxes

     

    44,637,000

     

     

    (1,382,000)

     

    47,722,000

     

    (6,223,000)

    Income tax (expense) benefit

     

    (3,504,000)

     

     

    6,000

     

     

    (3,510,000)

     

     

    12,000

    Net income (loss) from continuing operations

     

    41,133,000

     

    (1,376,000)

     

    44,212,000

     

    (6,211,000)

    Net loss from discontinued operations, net of taxes

     

    —

     

     

    —

     

     

    —

     

     

    (1,698,000)

    Net income (loss)

     

    41,133,000

     

    (1,376,000)

     

    44,212,000

     

    (7,909,000)

    Net loss attributable to non-controlling interest

     

    1,083,000

     

     

    —

     

     

    3,000

     

     

    —

    Net income (loss) attributable to Ault Global Holdings

     

    42,216,000

     

    (1,376,000)

     

    44,215,000

     

    (7,909,000)

    Preferred dividends

     

    (4,000)

     

     

    (3,000)

     

     

    (9,000)

     

     

    (7,000)

    Net income (loss) available to common stockholders

    $

    42,212,000

    $

    (1,379,000)

    $

    44,206,000

    $

    (7,916,000)

     

     

     

     

     

     

     

     

    Basic net income (loss) per common share:

     

     

     

     

     

     

     

    Continuing operations

    $

    0.82

    $

    (0.24)

    $

    0.97

    $

    (1.20)

    Discontinued operations

     

    —

     

     

    —

     

     

    —

     

     

    (0.33)

    Net income (loss) per common share

    $

    0.82

    $

    (0.24)

    $

    0.97

    $

    (1.52)

     

     

     

     

     

     

     

     

    Diluted net income (loss) per common share:

     

     

     

     

     

     

     

    Continuing operations

    $

    0.79

    $

    (0.24)

    $

    0.91

    $

    (1.20)

    Discontinued operations

     

    —

     

     

    —

     

     

    —

     

     

    (0.33)

    Net income (loss) per common share

    $

    0.79

    $

    (0.24)

    $

    0.91

    $

    (1.52)

    Weighted average basic common shares outstanding

     

    50,783,000

     

     

    5,864,000

     

     

    45,052,000

     

     

    5,199,000

    Weighted average diluted common shares outstanding

     

    52,780,000

     

    5,864,000

     

    47,574,000

     

    5,199,000

     

     

     

     

     

     

     

     

    Comprehensive income (loss)

     

     

     

     

     

     

     

    Net income (loss) available to common stockholders

    $

    42,212,000

    $

    (1,379,000)

    $

    44,206,000

    $

    (7,916,000)

    Other comprehensive income (loss)

     

     

     

     

     

     

     

    Foreign currency translation adjustment

     

    134,000

     

    97,000

     

    41,000

     

    (51,000)

    Net unrealized gain (loss) on derivative securities of related party

     

    (5,893,000)

     

     

    761,000

     

     

    (2,924,000)

     

     

    (481,000)

    Other comprehensive income (loss)

     

    (5,759,000)

     

    858,000

     

    (2,883,000)

     

    (532,000)

    Total comprehensive income (loss)

    $

    36,453,000

     

    $

    (521,000)

     

    $

    41,323,000

     

    $

    (8,448,000)

     

    AULT GLOBAL HOLDINGS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

     

    For the Six Months Ended June 30,

    2021

    2020

     

    Cash flows from operating activities:

     

     

     

    Net income (loss)

    $

    44,212,000

    $

    (7,909,000)

    Less: Net loss from discontinued operations

     

    —

     

     

    (1,698,000)

    Net income (loss) from continuing operations

     

    44,212,000

     

    (6,211,000)

    Adjustments to reconcile net income (loss) to net cash used in operating activities:

     

     

    Depreciation

     

    446,000

     

    260,000

    Amortization

     

    191,000

     

     

    167,000

    Amortization of right-of-use assets

     

    441,000

     

    247,000

    Amortization, related party

     

    15,000

     

     

    —

    Interest expense – debt discount

     

    40,000

     

    908,000

    Gain on extinguishment of debt

     

    (929,000)

     

     

    —

    Change in fair value of warrant liability

     

    (290,000)

     

    10,000

    Accretion of original issue discount on notes receivable – related party

     

    (4,000)

     

     

    15,000

    Accretion of original issue discount on notes receivable

     

    (955,000)

     

    (4,000)

    Increase in accrued interest on notes receivable – related party

     

    (1,000)

     

     

    —

    Stock-based compensation

     

    584,000

     

    143,000

    Realized losses on other investments

     

    —

     

     

    28,000

    Realized gains on sale of marketable securities

     

    (12,283,000)

     

    (15,000)

    Unrealized gains on marketable equity securities

     

    (3,483,000)

     

     

    (52,000)

    Unrealized (gains) losses on equity securities – related party

     

    (39,852,000)

     

    65,000

    Unrealized (gains) losses on equity securities

     

    (1,224,000)

     

     

    73,000

    Changes in operating assets and liabilities:

     

     

     

    Marketable equity securities

     

    (9,616,000)

     

    —

    Accounts receivable

     

    (887,000)

     

     

    199,000

    Accrued revenue

     

    78,000

     

    34,000

    Inventories

     

    485,000

     

     

    (35,000)

    Prepaid expenses and other current assets

     

    (2,537,000)

     

    181,000

    Other assets

     

    (246,000)

     

     

    (39,000)

    Accounts payable and accrued expenses

     

    (2,651,000)

     

    1,365,000

    Accounts payable, related parties

     

    (36,000)

     

     

    (24,000)

    Income taxes payable

     

    2,770,000

     

     

    Other current liabilities

     

    4,472,000

     

    660,000

    Lease liabilities

     

    (439,000)

     

     

    (234,000)

    Net cash used in continuing operating activities

     

    (21,699,000)

     

    (2,259,000)

    Net cash provided by discontinued operating activities

     

    —

     

     

    1,000

    Net cash used in operating activities

     

    (21,699,000)

     

    (2,258,000)

     

     

     

     

    Cash flows from investing activities:

     

     

     

    Purchase of property and equipment

     

    (5,590,000)

     

    (190,000)

    Investment in promissory notes, related parties

     

    (4,040,000)

     

     

    (199,000)

    Investments in common stock and warrants, related parties

     

    (16,483,000)

     

    (10,000)

    Investment in real property, related party

     

    (2,670,000)

     

     

    —

    Proceeds from sale of investment in real property, related party

     

    2,670,000

     

    —

    Purchase of marketable equity securities

     

    —

     

     

    —

    Sales of marketable equity securities

     

    430,000

     

    110,000

    Proceeds from loans receivable

     

    —

     

     

    140,000

    Investments in debt and equity securities

     

    (4,054,000)

     

    (3,000)

    Net cash used in investing activities

    $

    (29,737,000)

     

    $

    (152,000)

    AULT GLOBAL HOLDINGS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (continued)

     

    For the Six Months Ended June 30,

    2021

    2020

     

    Cash flows from financing activities:

     

     

     

    Gross proceeds from sales of common stock

    $

    144,044,000

    $

    —

    Financing cost in connection with sales of equity securities

     

    (4,541,000)

     

     

    —

    Proceeds from convertible notes payable

     

    —

     

    100,000

    Proceeds from notes payable

     

    500,000

     

     

    3,148,000

    Proceeds from short-term advances – related party

     

    —

     

    604,000

    Payments on short-term advances – related party

     

    —

     

     

    (98,000)

    Payments on notes payable

     

    (1,917,000)

     

    (186,000)

    Payments on advances on future receipts

     

    -

     

     

    (20,000)

    Payments of preferred dividends

     

    (9,000)

     

    (7,000)

    Payments on revolving credit facilities, net

     

    (23,000)

     

     

    68,000

     

     

    Net cash provided by financing activities

     

    138,054,000

     

    3,609,000

     

     

     

     

    Effect of exchange rate changes on cash and cash equivalents

     

    93,000

     

     

    9,000

     

    Net increase in cash and cash equivalents

     

    86,711,000

     

     

    1,208,000

     

    Cash and cash equivalents at beginning of period

     

    18,680,000

     

     

    483,000

     

     

    Cash and cash equivalents at end of period

    $

    105,391,000

    $

    1,691,000

     

     

     

     

    Supplemental disclosures of cash flow information:

    Cash paid during the period for interest

    $

    658,000

     

    $

    71,000

     

    Non-cash investing and financing activities:

     

     

     

    Cancellation of convertible notes payable into shares of common stock

    $

    —

    $

    2,689,000

    Cancellation of notes payable into shares of common stock

    $

    449,000

     

    $

    —

    Payment of accounts payable with digital currency

    $

    119,000

    $

    —

    Issuance of common stock in payment of liability

    $

    —

     

    $

    229,000

    Cancellation of short-term advances, related party into shares of common stock

    $

    —

    $

    740,000

    Issuance of notes payable and convertible notes payable in payment of accrued expenses

    $

    —

     

    $

    420,000

    Conversion of debt and equity securities to marketable securities

    $

    2,656,000

    $

    —

    Conversion of loans to debt and equity securities

    $

    150,000

     

    $

    —

    Conversion of convertible notes payable, related party into shares

    of common stock

    $

    400,000

     

    $

    —

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210816005229/en/

    Get the next $ALZN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ALZN
    $DPW

    CompanyDatePrice TargetRatingAnalyst
    Alzamend Neuro Inc.
    $ALZN
    10/1/2021$8.00Buy
    Ascendiant Capital Markets
    More analyst ratings

    $ALZN
    $DPW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Horne William B. bought $3,285 worth of shares (3,334 units at $0.99), increasing direct ownership by 13% to 30,000 units (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      3/27/25 7:30:10 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ault Milton C Iii bought $2,969 worth of shares (2,905 units at $1.02) (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      3/25/25 4:30:07 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Katzoff David J bought $5,048 worth of shares (5,000 units at $1.01), increasing direct ownership by 926% to 5,540 units (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      3/24/25 7:30:07 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALZN
    $DPW
    Leadership Updates

    Live Leadership Updates

    See more
    • Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board

      Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the appointment of Dr. Terri Hunter, Ph.D., a Technology Transfer Specialist, to its Scientific Advisory Board. During her tenure at the University of South Florida ("USF"), Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend's two product candidates, AL001 and AL002. AL001 is a novel lithium-delivery system; it is a lithium-salicylate-L-proline engineered ionic co-crystal under development as an oral treatment for patients with demen

      4/4/22 8:00:00 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ault Global Holdings Announces Adtech Pharma, Inc., an Innovative Biotech, Appoints Jodi Brichan to Its Board of Directors

      Ault Global Holdings, Inc. (NYSE:DPW) a diversified holding company (the "Company"), announced that Adtech Pharma, Inc. ("Adtech"), has appointed Jodi Brichan, to its Board of Directors. Ms. Brichan was a member of the board of directors of the Company until August 13, 2021. In June of 2021, the Company entered a securities purchase agreement (the "Agreement") with Adtech that granted the Company the right to acquire up to 40% of the current equity in Adtech, an innovative biotechnology company, for $3 million. The right to appoint Ms. Brichan was provided for in the Agreement. The investment in Adtech was made through Digital Power Lending, LLC, a wholly owned subsidiary of the Company. J

      9/27/21 6:30:00 AM ET
      $DPW
      Industrial Machinery/Components
      Capital Goods
    • Ault Global Holdings, Inc. Announces Results of Annual Meeting of Stockholders

      Ault Global Holdings, Inc. (NYSE:DPW) a diversified holding company ("AGH," or the "Company"), announced the results of the Company's 2021 Annual Meeting of Stockholders (the "Meeting"), which was held today, August 13, 2021, at 9:00 a.m. PT, and at which time the seven proposals voted upon, as set forth in the Company's Definitive Proxy Statement dated June 7, 2021 (the "Proxy Statement"), were approved by the stockholders. At the Meeting, the stockholders voted upon and approved the following proposals as described in the Proxy Statement: Election of the eight (8) director nominees named in the Proxy Statement to hold office until the next annual meeting of stockholders; Ratificatio

      8/13/21 4:15:00 PM ET
      $DPW
      Industrial Machinery/Components
      Capital Goods

    $ALZN
    $DPW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ascendiant Capital Markets initiated coverage on Alzamend Neuro with a new price target

      Ascendiant Capital Markets initiated coverage of Alzamend Neuro with a rating of Buy and set a new price target of $8.00

      10/1/21 7:11:54 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALZN
    $DPW
    Financials

    Live finance-specific insights

    See more
    • BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

      BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company"), reported its financial results for the third quarter ended September 30, 2022 on its Form 10-Q filed with the Securities and Exchange Commission. Third quarter 2022 highlights include: Total assets of $610.9 million as of September 30, 2022; Positive working capital of $25.7 million as of September 30, 2022; Cash and cash equivalents of $10.1 million as of September 30, 2022; Revenue from cryptocurrency mining of $3.9 million, compared to $0.3 million in the prior third fiscal quarter; Revenue from the Company's majority owned subsidiary, The Singing Machine Company, Inc. (NASDAQ:MICS)

      11/21/22 7:27:00 PM ET
      $ALZN
      $MICS
      $NILE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Diversified Electronic Products
      Consumer Staples
    • BitNile Holdings Reports Second Quarter 2022 Financial Results

      BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company"), reported its financial results for the second quarter ended June 30, 2022 on its Form 10-Q filed with the Securities and Exchange Commission. Second quarter 2022 highlights include: Total assets of $596.3 million as of June 30, 2022; Positive working capital of $51.4 million as of June 30, 2022; Cash and cash equivalents of $24.1 million as of June 30, 2022; Revenue from cryptocurrency mining of $4.0 million, compared to $0.3 million in the prior second fiscal quarter; Revenue from hotel operations of $4.6 million, compared to $0 in the prior second fiscal quarter; Revenue from lendi

      8/23/22 6:30:00 AM ET
      $ALZN
      $NILE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Military/Government/Technical
      Industrials
    • BitNile Holdings Reports 2021 Year-End Results

      The Company Grows Revenue by 120% to $52 Million and Ends the Year with $490 Million in Assets BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company") today announced its financial results for the year ended December 31, 2021 contained within its Form 10‑K filed with the Securities and Exchange Commission. Year ended December 31, 2021 highlights: Revenue of $52.4 million, an increase of 120% from $23.9 million in the prior fiscal year; Revenue from lending and trading activities of $16.9 million due to the allocation of capital to Digital Power Lending, LLC ("DP Lending"); Revenue from trading activities during the year ended December 31, 2021

      4/18/22 6:30:00 AM ET
      $ALZN
      $NILE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Military/Government/Technical
      Industrials

    $ALZN
    $DPW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ault Milton C Iii sold $6,196 worth of shares (1,224 units at $5.06), decreasing direct ownership by 0.59% to 1,843 units (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      5/14/25 5:00:07 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Horne William B. bought $3,285 worth of shares (3,334 units at $0.99), increasing direct ownership by 13% to 30,000 units (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      3/27/25 7:30:10 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ault Milton C Iii bought $2,969 worth of shares (2,905 units at $1.02) (SEC Form 4)

      4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

      3/25/25 4:30:07 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALZN
    $DPW
    SEC Filings

    See more
    • Amendment: SEC Form 144/A filed by Alzamend Neuro Inc.

      144/A - Alzamend Neuro, Inc. (0001677077) (Subject)

      7/11/25 7:15:38 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alzamend Neuro Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Alzamend Neuro, Inc. (0001677077) (Filer)

      7/9/25 4:30:40 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Alzamend Neuro Inc.

      144 - Alzamend Neuro, Inc. (0001677077) (Subject)

      5/9/25 7:49:16 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALZN
    $DPW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Alzamend Neuro Inc. (Amendment)

      SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)

      2/2/24 4:38:42 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Alzamend Neuro Inc. (Amendment)

      SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)

      1/25/24 5:21:29 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Alzamend Neuro Inc. (Amendment)

      SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)

      11/15/22 4:30:13 PM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALZN
    $DPW
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

      ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that it has completed the final closing of its $5 million private placement. As previously reported, on February 28, 2025, Alzamend entered into a Securities Purchase & Exchange Agreement (the "Agreement") with a sophisticated investor (the "Investor"), pursuant to which Alzamend agreed to sell to the Investor up to 500 shares of Series C Conver

      6/16/25 8:00:00 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

      Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced the dosing of the first patient of its first Phase II clinical study of AL001, in healthy human subjects. This study follows th

      5/29/25 8:00:00 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

      Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 19, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced the enrollment of the first patient of its first Phase II clinical study of AL001, in healthy human subjects. This study follow

      5/19/25 8:00:00 AM ET
      $ALZN
      Biotechnology: Pharmaceutical Preparations
      Health Care